Technical Analysis for SHPG - Shire plc

Grade Last Price % Change Price Change
grade B 170.99 -0.15% -0.26
SHPG closed down 1.0 percent on Friday, July 20, 2018, on 62 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Jul 31

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical SHPG trend table...

Date Alert Name Type % Chg
Jul 20 Cup with Handle Other -0.15%
Jul 20 Overbought Stochastic Strength -0.15%
Jul 19 Cup with Handle Other -1.15%
Jul 19 Overbought Stochastic Strength -1.15%
Jul 19 Up 3 Days in a Row Strength -1.15%
Jul 18 Cup with Handle Other -1.01%
Jul 18 Overbought Stochastic Strength -1.01%
Jul 17 Outside Day Range Expansion -0.90%
Jul 17 Overbought Stochastic Strength -0.90%
Jul 16 Cup with Handle Other -0.62%

Older signals for SHPG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). The SP segment offers products for the treatment of attention deficit and hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. The HGT segment offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. The RM segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of behavioral health, gastrointestinal, HGT, RM, and other therapeutic areas. The company markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. It has operations in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.
Is SHPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 177.51
52 Week Low 122.9082
Average Volume 985,465
200-Day Moving Average 150.2328
50-Day Moving Average 166.1158
20-Day Moving Average 169.2565
10-Day Moving Average 172.315
Average True Range 2.1539
ADX 30.09
+DI 31.1917
-DI 17.2598
Chandelier Exit (Long, 3 ATRs ) 167.4283
Chandelier Exit (Short, 3 ATRs ) 164.5117
Upper Bollinger Band 177.447
Lower Bollinger Band 161.066
Percent B (%b) 0.62
BandWidth 9.67821
MACD Line 2.532
MACD Signal Line 2.5147
MACD Histogram 0.0173
Fundamentals Value
Market Cap 51.01 Billion
Num Shares 298 Million
EPS 2.23
Price-to-Earnings (P/E) Ratio 76.79
Price-to-Sales 2.82
Price-to-Book 1.34
PEG Ratio 0.84
Dividend 0.92
Dividend Yield 0.54%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 174.27
Resistance 3 (R3) 174.49 173.70 173.76
Resistance 2 (R2) 173.70 172.94 173.59 173.59
Resistance 1 (R1) 172.48 172.46 172.09 172.26 173.43
Pivot Point 171.69 171.69 171.50 171.58 171.69
Support 1 (S1) 170.47 170.93 170.08 170.25 169.07
Support 2 (S2) 169.68 170.45 169.57 168.91
Support 3 (S3) 168.46 169.68 168.74
Support 4 (S4) 168.24